HDAC6-IN-11

HDAC6-IN-11 (Compound 9) is a selective HDAC6 inhibitor with the IC50 value of 20.7 nM. HDAC6-IN-11 has more than 300-fold selectivity over HDAC other isoforms. HDAC6-IN-11 shows anti-proliferative activities against cancer cells[1].

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC

Signaling Pathways >> Epigenetics >> HDAC

HDAC6:20.7 nM (IC50)

HDAC8:7750 nM (IC50)

HDAC6-IN-11 (0.44-6.68 μM, 48 h) treatment shows anti-proliferative activities against A549 and HCT116 cells[1]. HDAC6-IN-11 (0-20 μM, 48 h) treatment can increase the acetylation status of H3 and tubulin[1]. Cell Proliferation Assay[1] Cell Line: A549 and HCT116 cells Concentration: 0.44-6.68 μM Incubation Time: 48 hours Result: Showed anti-proliferative activities to A549 and HCT116 cells (GI50=3.2 and 1.82 μM, respectively). Western Blot Analysis[1] Cell Line: HCT116 cells Concentration: 0, 0.6, 1.25, 2.5, 5, 10 and 20 μM Incubation Time: 48 hours Result: Led to the increase of acetylation status of H3 and tubulin in a dose-dependent manner, and upregulated acetylated tubulin.

[1]. Shih-Wei Wang, et al. Synthesis and biological evaluation of 2-quinolineacrylamides. Bioorg Med Chem. 2020 Feb 1;28(3):115250.